Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study

Schizophr Res. 2017 Oct:188:110-117. doi: 10.1016/j.schres.2017.01.026. Epub 2017 Jan 23.

Abstract

Alterations of immune function have been reported in ultra-high risk (UHR) for psychosis patients causing expectations in terms of predictive meaningfulness and benefits of anti-inflammatory agents. According to a RCT in UHR-patients supplementation of omega-3 polyunsaturated fatty acids (PUFA) was effective in reducing transition to psychosis risk and to improve symptomatology. Based on preclinical findings, we now investigated state marker properties of and the influence of PUFA on immune markers in a RCT (clinical trials.gov Identifier: NCT00396643). In a longitudinal design we measured plasma levels of the pro-inflammatory interleukin 6 (IL-6), the soluble alpha (Tac) subunit of the interleukin 2 receptor (sIL-2r), and the circulating soluble form of the intercellular adhesion molecule one (sICAM-1), in 79 help-seeking UHR individuals (13-25years of age). Using linear mixed model (LMM) analysis, we investigated the effects of 12weeks supplementation of either 1.2g/d PUFA (n=38) or Placebo (n=41). At baseline, inflammatory markers were not altered in patients who later suffered transition to psychosis within one year (n=12; 11 PUFA-group, 1 PL-group). IL-6 was weakly inverse associated with omega-6 PUFA, and highly increased in nicotine users. In univariate tests of the LMM omega-3 PUFA caused a significant increase of sICAM-1 (p=0.022). PUFA did not significantly influence IL-6 or sIL-2r. The enhancement of sICAM-1 in the PUFA condition is suggestive for supportive effects on vascular immune response and immediate Th1 helper cell mediated immune answer, which was found disturbed in manifest schizophrenia, e.g. by facilitating the leukocyte adhesion and migration across the endothelium.

Keywords: At-risk mental state; Biomarker; Cytokines; Endothelium; Immune function; Indicated prevention; Inflammation; Interleukins; Psychosis.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / blood
  • Cross-Sectional Studies
  • Dietary Supplements*
  • Disease Progression
  • Double-Blind Method
  • Fatty Acids, Omega-3 / administration & dosage*
  • Female
  • Humans
  • Intercellular Adhesion Molecule-1 / blood
  • Interleukin-2 Receptor alpha Subunit / blood
  • Interleukin-6 / blood
  • Male
  • Patient Acceptance of Health Care
  • Prodromal Symptoms
  • Psychotic Disorders / blood
  • Psychotic Disorders / diet therapy*
  • Psychotic Disorders / immunology*
  • Psychotic Disorders / prevention & control
  • Risk
  • Treatment Outcome
  • Young Adult

Substances

  • Biomarkers
  • Fatty Acids, Omega-3
  • IL6 protein, human
  • Interleukin-2 Receptor alpha Subunit
  • Interleukin-6
  • Intercellular Adhesion Molecule-1

Associated data

  • ClinicalTrials.gov/NCT00396643